SELLAS Life Sciences Provides Update On Phase 3 REGAL Clinical Trial For Galinpepimut-S In Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences has provided an update on its Phase 3 REGAL clinical trial for Galinpepimut-S in Acute Myeloid Leukemia. The company expects to complete enrollment ex-China in November 2023 and commence enrollment in China this quarter.
October 12, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SELLAS Life Sciences' update on its Phase 3 REGAL clinical trial for Galinpepimut-S could potentially impact its stock. The completion of enrollment ex-China by November 2023 and the commencement of enrollment in China this quarter could be seen as positive developments.
The update on the Phase 3 REGAL clinical trial for Galinpepimut-S by SELLAS Life Sciences is a significant development for the company. The completion of enrollment ex-China by November 2023 and the commencement of enrollment in China this quarter could be seen as positive developments, potentially leading to a positive impact on the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100